Study on JNJ-90014496 for Treating B-Cell Non-Hodgkin Lymphoma

Inclusion Criteria

• Must be 18 years or older.
• Cancer must be confirmed to have CD19 and/or CD20 proteins.
• For Phase 1b:
  • Relapsed or refractory aggressive large B-cell NHL or follicular lymphoma (FL) Grade 3b: Must have had at least 2 previous treatments or 1 treatment if not eligible for high-dose chemotherapy and stem cell transplant.
  • Relapsed or refractory FL Grade 1-3a and marginal zone lymphoma: Must have had at least 2 previous treatments and prior exposure to an anti-CD20 antibody.
  • Frontline high-risk DLBCL: Must have DLBCL or high-grade B-cell lymphoma with remaining cancer after 2 or 3 cycles of initial chemoimmunotherapy.
• For Phase 2:
  • Must have large B-cell lymphoma, follicular large B-cell lymphoma, or transformed indolent lymphoma.
  • Must have had at least 2 previous treatments, including anthracycline chemotherapy and an anti-CD20 antibody.
  • Cancer must have returned or not responded to the most recent treatment.
• Must have measurable disease.
• Must have a performance status score of 0 to 2, indicating full activity or some restriction in strenuous activities.

Exclusion Criteria

• History of serious blood clots or lung clots within six months.
• History of stroke, severe heart problems, or heart rhythm issues within six months.
• History of seizures, dementia, or other serious brain disorders.
• History of optic neuritis or other immune-related brain diseases.
• Active liver or bile duct disease, except for certain conditions like Gilbert's syndrome.
• Active infections requiring treatment.
• Certain types of lymphoma or other specific conditions.
• Previous solid organ or allogeneic stem cell transplant.
• Recent autologous stem cell transplant within 12 weeks.
• For those previously treated with CAR-T: No CAR-T therapy within 12 weeks.